Postoperative Management of Diabetes and Chronic Liver Disease After Valve Surgery
This patient requires immediate transition to insulin therapy postoperatively, with a basal-bolus regimen targeting blood glucose 100-180 mg/dL, while chronic liver disease management focuses on multidisciplinary monitoring for decompensation and optimization of cardiovascular risk factors. 1
Immediate Postoperative Diabetes Management
Transition from IV to Subcutaneous Insulin
Stop intravenous insulin infusion only when blood glucose is stable ≤180 mg/dL (10 mmol/L) and oral feeding resumes. 1
Administer basal insulin 2-4 hours before stopping IV insulin to prevent rebound hyperglycemia and avoid ketoacidosis. 1
Calculate subcutaneous insulin dose based on the 24-hour IV insulin requirement: Half the total IV insulin dose becomes basal (long-acting) insulin, and the other half becomes rapid-acting insulin divided across meals. 1
Alternative approach: Give 75-80% of the total IV insulin dose as basal insulin, with rapid-acting insulin added at the first meal. 1
For patients not previously on insulin with short IV insulin duration (<24 hours): Start at 0.5-1 IU/kg body weight, split equally between basal and rapid-acting insulin. 1
Blood Glucose Targets and Monitoring
Maintain perioperative blood glucose between 100-180 mg/dL (5.6-10.0 mmol/L). 1
Monitor capillary blood glucose frequently to detect both hypoglycemia and hyperglycemia, especially given the patient's suboptimal control (HbA1c 8%). 1
Do not use CGM alone for glucose monitoring during the immediate postoperative period. 1
Medication Adjustments
Hold metformin on the day of surgery and resume only when renal function is stable and oral intake adequate. 1
SGLT2 inhibitors should have been discontinued 3-4 days before surgery (if applicable). 1
Other oral agents remain held until stable oral intake and glucose control are achieved. 1
Management of Glycemic Complications
Hypoglycemia Protocol
Treat any blood glucose <60 mg/dL (3.3 mmol/L) immediately with glucose, even without symptoms. 1
Use oral glucose (15-20g) if the patient is conscious and able to swallow; otherwise, administer IV dextrose immediately. 1
Increase monitoring frequency due to hypoglycemia unawareness risk in hospitalized patients. 1
Hyperglycemia Management
For blood glucose >300 mg/dL (16.5 mmol/L), check for ketones immediately if the patient has type 1 diabetes or is insulin-dependent. 1
If ketones are present, suspect diabetic ketoacidosis: Administer rapid-acting insulin, ensure adequate hydration, and consider ICU transfer. 1
In type 2 diabetes, severe hyperglycemia may indicate hyperosmolar hyperglycemic state: Check serum osmolality (>320 mOsm/L confirms diagnosis) and transfer to ICU for aggressive management. 1
Chronic Liver Disease Management
Perioperative Risk Stratification
Patients with chronic liver disease undergoing cardiac surgery face significantly elevated risks of bleeding, infection, and mortality. 2, 3
The Child-Pugh score and MELD score are the most reliable predictors of postoperative morbidity and mortality in cirrhotic patients. 3, 4
Multidisciplinary team involvement is essential for managing hepatic, cardiac, and metabolic complications. 3
Specific Postoperative Liver Considerations
Monitor closely for hepatic decompensation: Watch for worsening ascites, encephalopathy, variceal bleeding, and hepatorenal syndrome. 3, 4
Optimize ascites management with diuretics to prevent postoperative ascites leak and reduce risk of spontaneous bacterial peritonitis. 4
Correct coagulopathy aggressively given the liver's central role in coagulation homeostasis and increased bleeding risk post-cardiac surgery. 2, 4
Implement digestive decontamination and adjusted anti-infective therapy to reduce bacterial infection risk, which is significantly elevated in cirrhotic patients undergoing cardiopulmonary bypass. 2
Avoid nephrotoxic agents and monitor renal function closely to prevent hepatorenal syndrome. 2, 3
Long-Term Valve and Cardiovascular Management
Optimize guideline-directed medical therapy for any coexistent heart failure. 5
Manage cardiovascular risk factors (hypertension, hyperlipidemia) identically to patients without valve intervention, though medication choices must account for hepatic metabolism and bleeding risk. 5
Antithrombotic therapy depends on valve type: Mechanical valves require lifelong vitamin K antagonist therapy; bioprosthetic valves and repairs may require shorter-duration antithrombotic therapy. 5
Follow-up in a dedicated valve clinic provides optimal surveillance echocardiography and access to multidisciplinary care. 5
Critical Pitfalls to Avoid
Never stop IV insulin before administering subcutaneous basal insulin (2-4 hour overlap required) to prevent dangerous rebound hyperglycemia. 1
Do not resume metformin without confirming stable renal function, especially given the stress of surgery and potential hepatorenal complications. 1
Avoid underestimating infection risk in cirrhotic patients post-cardiac surgery; maintain high suspicion and low threshold for cultures and antibiotics. 2, 3
The HbA1c of 8% indicates suboptimal preoperative control, which independently increases risk of complications, readmissions, and mortality. 6 This patient requires intensive glucose management and likely long-term insulin therapy.
Hepatic dysfunction alters drug metabolism: Carefully dose all medications and monitor for toxicity, particularly with insulin (increased half-life in liver disease). 3, 4